Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-28
2005-06-28
Raymon, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S248000, C514S252030, C514S279000, C514S300000, C514S303000, C544S236000, C544S237000, C544S238000, C544S268000, C546S113000, C546S268100
Reexamination Certificate
active
06911440
ABSTRACT:
The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I,the substituents being defined in the specification;as well as to new phthalazine derivatives; processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.
REFERENCES:
patent: 2960504 (1960-11-01), Marxer et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 6514974 (2003-02-01), Bold et al.
patent: 6686347 (2004-02-01), Bold et al.
patent: 0 722 936 (1996-07-01), None
patent: 871753 (1961-06-01), None
patent: 1293565 (1972-10-01), None
patent: WO 98/35958 (1998-08-01), None
Hennequin et al., “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,” J. Med. Chem., vol. 42, No. 26, pp. 5369-5389 (1999).
Ishihara H. et al., “Pharmacological Characterization of a novel, potent and selective phosphodiesterase 5 inhibitor, E4010,” Jpn. J. Pharmacol., vol. 76, p. 175 (1998).
Watanabe N. et al., “4-benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5,” J. Med. Chem., vol. 41, pp. 3367-3372 (1998).
Bold Guido
Frei Jörg
Heng Richard
King Janet Dawson
Manley Paul William
McNally Lydia T.
Novartis AG
Patel Sudhaker B.
Raymon Richard L.
LandOfFree
Phthalazine derivatives for treating inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazine derivatives for treating inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazine derivatives for treating inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486334